All 1 tracked stories fall under one category: market-trends. HMI-115 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 10 original sources each against 3.3 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Center for Drug Evaluation
All 1 tracked stories fall under one category: market-trends. HMI-115 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 10 original sources each against 3.3 for the same window. At 7, the average consequence score sits above the same-window beat average of 6.6. We currently track 1 Healthcare story that mention Center for Drug Evaluation, all published on March 25, 2026.
Stories tracked
1
Sources per story
10
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Center for Drug Evaluation. Shared-story counts are live from our verified record — not editorial picks.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.